Urinary Tract Infection Therapeutics Market Size, Share & Trends Analysis Report By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, Other Indications) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global urinary tract infection therapeutics market size was valued at USD 8.92 billion in 2022. It is estimated to reach an expected value of USD 11.85 billion by 2031, registering a CAGR of 3.2% during the forecast period (2023-2031). Factors such as increasing prevalence of diabetes, kidney stones and launch of combination drugs, significanly drives the urinary tract infection therapeutics market demand by 2031.

Patients with crucial issues and diabetes are vulnerable to various infectious diseases. The patient is vulnerable to urinary tract infections. Some of the symptoms in these patients include urination, pain, and irritation. UTI is a disease that affects over 15% of the population. This infection can affect people of all ages. The rising Prevalence of Diabetes and kidney stones raises the number of urinary tract infection (UTI) cases, which raises drug demand, driving the global urinary tract infection market for therapeutics. The combination drugs are effective against these infections. The availability of such a diverse range of therapeutics is expected to drive demand for UTI treatment in the market. The growing geriatric population creates a high demand for the market. The elderly are particularly vulnerable to such infections. UTI is a common problem among older women over the age of 65. The aging population will have a positive impact on the UTI treatment market. All these UTI treatment market drivers will contribute to the treatment market's exceptional growth rate.

Market Dynamics

Global urinary tract infection therapeutics market drivers

Increasing prevalence of diabetes and kidney stones

With the rising Prevalence of Diabetes and kidney stones, the number of urinary tract infection (UTI) cases rises, driving the global urinary tract infection therapeutics market growth. According to the International Federation of Diabetics 2021, in 2020, Diabetes affected approximately 463 million adults aged 20 to 79 years; by 2030, which is expected to rise to 643 million, and by 2045, it is expected to reach 700 million. In several countries, the proportion of people with type 2 diabetes is increasing. Diabetes affects 79% of adults in low- and middle-income countries. Because the sugar in the urine serves as a breeding ground for bacteria, urinary tract infections can be particularly problematic for people with diabetes. As a result, the demand for UTI therapy treatment in such cases has increased. As a result, it is expected to boost the market under consideration.

According to the American Academy of Family Physicians (AAFP), kidney stones are a prevalent illness, with an annual incidence of eight cases per 1,000 adults. In addition, approximately 13% of men and 7% of women may get kidney stones at some point in their lives, and in the US, the incidence of urinary retention ranges from 4.5 to 6.8 per 1,000 males per year. According to the study titled “Prevalence and Associated Factors of Urinary Tract Infections among Diabetic Patients,” published in Health Science Journal 2019, UTI was found to be 38 % more common in diabetic patients. UTI was found to be more common in females, accounting for 63.16 % of all cases, while males contributed 36.84 % of all cases among the subjects studied. The leading cause of UTI in diabetic patients is high blood sugar levels. Thus, owing to the abovementioned factors, the studied market is expected to grow significantly over the forecast period.

Launch of combination drugs

The combination drugs prove efficient for these infections. The availability of this wide range of therapeutics is expected to boost the UTI treatment market demand. In July 2019, the FDA will continue to encourage the development of new, secure antibacterial medications to give patients more options for treating severe infections, for example. Adults with complicated urinary tract infections (cUTI) and intra-abdominal infections may use Recarbrio (imipenem, cilastatin, and relebactam), an antibacterial medication, according to the United States Food and Drug Administration. Merck & Co. Inc. received FDA approval for Recarbrio as a treatment. So, it is anticipated that introducing the chaos combination drug will propel the market during the forecast period.

Lefamulin, a pleuromutilin antibiotic that inhibits the large subunit of bacterial ribosomes, was also approved for medical use in the United States in August 2019 and the European Union in July 2020. A novel combination antibiotic for treating patients with specific confirmed or suspected Gram-negative bacterial infections requiring hospitalization, Zavicefta, was similarly announced by Pfizer Inc. in July 2018 that it is now available in the UK and Germany. Pfizer similarly launched Zavicefta in additional international markets at the end of 2018. The creation of Zavicefta was prompted by the requirement for new antibiotics for difficult-to-treat Gram-negative bacteria, many of which have become increasingly resistant to the antibiotics currently available. Furthermore, in February 2020, a French pharmaceutical company announced Exblifep, a combination of enmetazobactam, a novel extended-spectrum beta-lactamase inhibitor, and cefepime, a fourth-generation cephalosporin that met primary endpoints in a clinical trial for complicated UTIs.

Global urinary tract infection therapeutics market restraint

Adverse effects associated with the use of medication

Every medication or medical procedure has some side effects. The common side effects of Urinary tract infection therapeutics are nausea and vomiting, dry mouth, and soreness. Throat, hoarseness, chills, shivering, confusion, fuzzy thinking, etc. However, according to the Center for Education & Research on Therapeutics, over 2 million adverse drug reactions (ADRs) cases are reported annually, leading to approximately 100,000 deaths. According to the FDA, it is estimated that, in the United States, over 350,000 ADRs occur in nursing homes each year. With an increase in the number of cases of ADRs being reported globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market. Side effects can include rash, dizziness, nausea, diarrhea, and yeast infections. More severe side effects can include antibiotic-resistant infections side effects associated with standard UTI therapies like fluoroquinolones, such as variations in blood sugar levels and central nervous system problems such as anxiety, seizures, and insomnia may impede urinary tract infection treatment market expansion to some extent during the forecast timeframe.

Global urinary tract infection therapeutics market opportunities

Research and development in uti treatment

Research and Development in UTI treatment are expected to provide lucrative growth opportunities for global urinary tract infection treatment market participants. For example, Lupin received approval from the US Food and Drug Administration (FDA) in July 2018 for generic Nitrofurantoin capsules. Alvogen Malta Operations Ltd sells a generic version of Macrodantin. It treats urinary tract infections caused by Staphylococcus aureus, enterococci, and other bacteria.

In addition, Spero Therapeutics, Inc. announced in May 2020 that patient enrollment in its Phase 3 clinical trial of tebipenem HBr to treat complicated urinary tract infection (UTI) and acute pyelonephritis, ADAPT-PO, had been completed (AP). The US FDA approved the Recarbrio drug in July 2019 to treat cUTI and complicated intra-abdominal infections in adults. Achaogen, Inc. received US FDA approval for ZEMDRI to treat cUTIs in adults in June 2018. Furthermore, in July 2019, Healthy.io, a developer of smartphone camera-based solutions, announced an agreement with Walgreens Boots Alliance, Inc. to place Healthy.io's Dip UTI test kits in Boots pharmacies across the globe. Thus, over the forecast period, there is a massive opportunity in the market, and it is expected to launch many therapeutic drugs over the studied period.

Regional Analysis

By region, the global urinary tract infections therapeutics market share is segmented into North America, Europe, Asia Pacific, South America, and MEA.

North america dominates the global market

North America dominated the market and is estimated to grow at a CAGR of 3.3% over the forecast period. Due to better healthcare infrastructure, effective government policies, a sizable base of multinational corporations, and a high level of public awareness regarding diagnostic testing and medical devices, the United States holds one of the most significant shares in the market under study. According to the American Academy of Family Physicians (AAFP), kidney stones are a prevalent illness, with an annual incidence of eight cases per 1,000 adults. FIn addition, approximately 13% of men and 7% of women may get kidney stones at some point in their lives, and in the US, the incidence of urinary retention ranges from 4.5 to 6.8 per 1,000 males per year. Moreover, there have recently been several Food and Drug Administration treatment approvals for UTIs. For instance, Recarbrio (imipenem, cilastatin, and relebactam) was licensed by the United States Food and Drug Administration to treat individuals with complex urinary tract infections (UTI) and complicated intra-abdominal infections (cIAI) in 2019. Therefore, owing to the above factors, the rise in urinary tract infection cases, kidney stones, and other associated diseases with urinary tract infections in the United States is expected to witness growth over the forecast period.

Europe is the second largest region. It is estimated to reach an expected value of USD 3188 million by 2031, registering a CAGR of 3.4%. Germany's urinary tract infection therapeutics market is expected to grow significantly during the forecast period because of the increasing Prevalence of urinary tract infections and kidney stones, the rising geriatric population, and increasing government initiatives. According to the article published by WA Manaco in springer journal 2021, Urinary tract infections (UTIs) are a frequent cause for patient in Germany who visits family medicine, with a prevalence ranging between 1.7 and 3.1%. Thus, increasing Prevalence in the country is expected to boost the market. The European government provides specific guidelines to prevent drug resistance. For instance, in a study published in BMJ open journal in 2021, titled “REDuction of Antibiotic Resistance (REDARES) in urinary tract infections using treatments according to national clinical guidelines,” through the study searcher identified therapeutic regime that can help in the reduction of antibiotics resistance. Thus, such a therapeutic regime minimized the resistance and increased the demand for antibiotics to treat UTI infection. It is expected to boost the market over the forecast period. 

Asia Pacific is the third largest region. China is among the fastest-growing regions in the pharmaceuticals domain. The primary reason for the urinary tract infections therapeutics market's growth is China’s rapidly aging population, which indicates that the country is expected to experience an explosion of chronic conditions and infectious diseases, which require drugs as a part of treatment which is expected to drive the urinary tract infection therapeutics market. For instance, in a study titled ‘Prevalence, incidence, and risk factors of urinary tract infection among immobile inpatients in China: a prospective, multicenter study in 2020, immobile inpatients have a high risk of urinary tract infection (UTI). A urinary tract infection (UTI) was found in 393 of the 23,985 immobile individuals. In hospitalized immobile patients, the frequency and incidence of UTIs were 1.64 % (393/23 985) and 0.69 per 1000 patient days, respectively. The catheter-associated UTI infection rate was 2.25 per 1000 urine catheter days. This drives the urinary tract infection therapeutics market, increasing the demand for therapeutics to treat urinary tract infections (UTIs).

Segmental Analysis

The global urinary tract infections therapeutics market share is segmented by drug, indication, and region.

By drug, the global market for urinary tract infection therapeutics market is bifurcated into penicillin and combinations, cephalosporin, azoles and amphotericin B, quinolones, nitrofurans, and other drugs. The quinolones drugs segment dominated the market and is expected to grow at a CAGR of 3% during the forecast period. Quinolone antibiotics are bactericidal antibiotics that destroy bacteria directly. They impede the action of bacterial type II topoisomerases, DNA gyrase, and topoisomerase IV, turning them into hazardous enzymes that cause irreversible double-stranded breaks in the chromosome. A study titled ‘Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis’ in 2021 reported that UTIs (urinary tract infections) are one of the most prevalent bacterial infections, both in the community and in hospitals. Fluoroquinolones, such as levofloxacin and ciprofloxacin, are commonly used to treat urinary tract infections, and this drives the market. Furthermore, a study titled ‘Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study in 2019 reported that Fluoroquinolones had been linked to better clinical outcomes in women with uncomplicated urinary tract infections, and this condition will improve the usage of quinolones by the patients and thus drives the market. Hence, owing to the above conditions, the quinolones segment of the urinary tract infection therapeutics market is expected to grow over the forecast period.

By indication, the global urinary tract infection therapeutics market is segmented into complicated UTI, uncomplicated UTI, and other indications. The complicated UTI segment dominated the market and is expected to grow at a CAGR of 3.5% during the forecast period. Infections that occur despite the presence of anatomical preventive measures (complex UTI in males) Infections that arise from anatomical anomalies, such as obstructions, hydronephrosis, renal tract calculi, or colovesical fistula. A study titled ‘Complicated Urinary Tract Infections in 2021 reported that Complicated urinary tract infections have a higher likelihood of treatment failure, necessitating longer antibiotic courses and, in some cases, further testing, and this condition depicts that complicated urinary tract infections lead to more prolonged usage of antibiotics, and this drives the urinary tract infection therapeutics market. In addition to the above, several key players submitted applications to the United States Food and Drug Administration Tebipenem HBr for the treatment of Complicated Urinary Tract Infections, including Pyelonephritis, has been submitted to the United States Food and Drug Administration by Spero Therapeutics, and this drives the market. Furthermore, Cefiderocol has been approved by the Food and Drug Administration for treating complex urinary tract infections (cUTIs) caused by gram-negative bacteria, including kidney infections, in patients with limited or no other treatment options, and this drives the market. Hence, the ongoing research studies, recent product developments, and launches are expected to boost the complicated UTI segment of the urinary tract infection therapeutics market due to the above conditions.

Recent Developments

• November 2022 - The top three ranking of AstraZeneca in the 2022 Access to Medicine Index (AMI) is a result of the company's pioneering efforts to improve international health systems and broaden patients' access to adequate, affordable treatments.
• November 2022 - Enhertu (trastuzumab deruxtecan), a product co-developed by AstraZeneca and Daiichi Sankyo, has been recommended for approval in the European Union (EU) as monotherapy to treat adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received a trastuzumab-based regimen.